Headquartered in New Haven, CT Fiscal year ends December NASDAQ: IVVD invivyd.com
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company focused on delivering protection from serious viral infectious diseases through monoclonal antibody (mAb) therapeutics. The company deploys a proprietary integrated technology platform designed to assess, monitor, develop, and adapt antibodies against evolving viral threats. Its commercial product, PEMGARDA (pemivibart), is authorized under FDA Emergency Use Authorization for the pre-exposure prophylaxis of COVID-19 in immunocompromised adults and adolescents. Invivyd is advancing VYD2311, a next-generation mAb candidate for COVID-19 prevention designed for intramuscular administration, currently in Phase 3 pivotal trials (DECLARATION and LIBERTY) with data expected in Q3 2026. The company is also expanding its pipeline beyond COVID-19 into measles (VMS063) and pediatric RSV prevention (VBY329), and is exploring VYD2311 in Long COVID through the SPEAR Study Group collaboration. Updated
Pre-Market Stock Futures: Futures are trading higher as we get ready to start a holiday-shortened trading week after an outstanding triple-witching Friday rally that may have kicked the “Santa Claus” rally into…
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company focused on delivering protection from serious viral infectious diseases through monoclonal antibody (mAb) therapeutics.
The Wall Street consensus 12-month price target for IVVD is $10.00.
